5 results on '"Randal A. Serafini"'
Search Results
2. Design of and outcomes in a student-run free mental health clinic serving the uninsured in East Harlem
- Author
-
Samuel K. Powell, Alexandra Saali, Justin Frere, Elizabeth Magill, Hannah Krystal, Randal A. Serafini, Syeda Sultana, Brandon Dale, Muhammad Ali, Vedika Kumar, Debjyoti Datta, Josimar Hernandez-Antonio, Anne Aronson, Yasmin S. Meah, Vicki Gluhoski, and Craig L. Katz
- Subjects
HEDIS ,Psychiatry ,Student-run free clinic ,Immigrants ,Patient outcomes ,RC435-571 - Abstract
Abstract Background Safety-net clinics are an important source of low-cost or free mental healthcare to those with limited financial resources. Such clinics are often staffed by trainees in early stages of their career. Only limited data exist on best practices in treatment-implementation and on clinical outcomes attained in such clinics. The primary purpose of this article is to describe the design of an outpatient psychiatry student-run free clinic (SRFC) serving uninsured individuals in New York City’s East Harlem neighborhood and to analyze the quality of services provided and the clinical outcomes attained. Methods The authors conducted a retrospective chart review of n = 69 patients treated in the EHHOP Mental Health Clinic (E-MHC) to describe the demographic and clinical characteristics of the study population. Utilizing Health Effectiveness Data and Information Set metrics, they estimated the likelihoods of patients meeting metric quality criteria compared to those in other New York State (NYS) insurance groups. The authors derived linear mixed effect and logistic regression models to ascertain factors associated with clinical outcomes. Finally, the authors collected patient feedback on the clinical services received using a customized survey. Results Almost all patients were of Hispanic ethnicity, and about half of patients had more than one psychiatric disorder. The clinical service performance of the E-MHC was non-inferior on most measures examined. Factors associated with symptom improvement were the number of treatment sessions and certain demographic and clinical variables. Patients provided highly positive feedback on the mental healthcare services they received. Conclusions SRFCs can provide quality care to vulnerable patients that leads to clinically meaningful reductions in psychiatric symptoms and is well-received by patients.
- Published
- 2022
- Full Text
- View/download PDF
3. Portable hardware & software technologies for addressing ophthalmic health disparities: A systematic review
- Author
-
Margarita Labkovich, Megan Paul, Eliott Kim, Randal A. Serafini, Shreyas Lakhtakia, Aly A Valliani, Andrew J Warburton, Aashay Patel, Davis Zhou, Bonnie Sklar, James Chelnis, and Ebrahim Elahi
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Vision impairment continues to be a major global problem, as the WHO estimates 2.2 billion people struggling with vision loss or blindness. One billion of these cases, however, can be prevented by expanding diagnostic capabilities. Direct global healthcare costs associated with these conditions totaled $255 billion in 2010, with a rapid upward projection to $294 billion in 2020. Accordingly, WHO proposed 2030 targets to enhance integration and patient-centered vision care by expanding refractive error and cataract worldwide coverage. Due to the limitations in cost and portability of adapted vision screening models, there is a clear need for new, more accessible vision testing tools in vision care. This comparative, systematic review highlights the need for new ophthalmic equipment and approaches while looking at existing and emerging technologies that could expand the capacity for disease identification and access to diagnostic tools. Specifically, the review focuses on portable hardware- and software-centered strategies that can be deployed in remote locations for detection of ophthalmic conditions and refractive error. Advancements in portable hardware, automated software screening tools, and big data-centric analytics, including machine learning, may provide an avenue for improving ophthalmic healthcare.
- Published
- 2022
- Full Text
- View/download PDF
4. HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice
- Author
-
Kerri D. Pryce, Kleopatra Avrampou, Lefteris Manouras, Valeria Cogliani, Vasiliki Mitsi, Venetia Zachariou, Olivier Berton, Farhana Sakloth, Randal A. Serafini, and Matthew Jarpe
- Subjects
Male ,SNi ,Inflammation ,Pharmacology ,Histone Deacetylase 6 ,Hydroxamic Acids ,Article ,Rats, Sprague-Dawley ,03 medical and health sciences ,Mice ,0302 clinical medicine ,medicine ,Animals ,Pain Measurement ,business.industry ,HDAC6 ,Nerve injury ,030227 psychiatry ,Peripheral ,Rats ,Histone Deacetylase Inhibitors ,Mice, Inbred C57BL ,Nociception ,Pyrimidines ,Hyperalgesia ,Neuropathic pain ,Peripheral nerve injury ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
BACKGROUND: HDAC6 is a class IIB histone deacetylase expressed at many levels of the nociceptive pathway. This study tested the ability of novel and selective HDAC6 inhibitors to alleviate sensory hypersensitivity behaviors in mouse models of peripheral nerve injury and peripheral inflammation. METHODS: We utilized the murine spared nerve injury (SNI) model for peripheral nerve injury and the Complete Freund’s Adjuvant (CFA) model of peripheral inflammation. We applied the Von Frey assay to monitor mechanical allodynia. RESULTS: Using the SNI model, we demonstrate that daily administration of the brain-penetrant HDAC6 inhibitor, ACY-738, abolishes mechanical allodynia in male and in female mice. Importantly, there is no tolerance to the antiallodynic actions of these compounds as they produce a consistent increase in Von Frey thresholds for several weeks. We observed a similar antiallodynic effect when utilizing the HDAC6 inhibitor, ACY-257, which shows limited brain expression when administered systemically. We also demonstrate that ACY-738 and ACY-257 attenuate mechanical allodynia in the CFA model of peripheral inflammation. CONCLUSIONS: Overall, our findings suggest that inhibition of HDAC6 provides a promising therapeutic avenue for the alleviation of mechanical allodynia associated with peripheral nerve injury and peripheral inflammation.
- Published
- 2020
5. RGS4 Maintains Chronic Pain Symptoms in Rodent Models
- Author
-
Li Shen, Sevasti Gaspari, Barbara Ligas, Aarthi Ramakrishnan, Vasiliki Mitsi, Claire Polizu, Kerri D. Pryce, Cole Swartz, Randal A. Serafini, Kleopatra Avrampou, Fiona B. Carr, Venetia Zachariou, Farhana Sakloth, and Abigail Richards
- Subjects
0301 basic medicine ,Male ,Down-Regulation ,Inflammation ,RGS4 ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Sex Factors ,medicine ,Animals ,Research Articles ,Pain Measurement ,Mice, Knockout ,biology ,business.industry ,General Neuroscience ,Chronic pain ,Nerve injury ,medicine.disease ,030104 developmental biology ,Allodynia ,Hyperalgesia ,Thalamic Nuclei ,Neuropathic pain ,biology.protein ,Female ,medicine.symptom ,Metabotropic glutamate receptor 2 ,Signal transduction ,Chronic Pain ,business ,Neuroscience ,030217 neurology & neurosurgery ,RGS Proteins ,Signal Transduction - Abstract
Regulator of G-protein signaling 4 (RGS4) is a potent modulator of G-protein-coupled receptor signal transduction that is expressed throughout the pain matrix. Here, we use genetic mouse models to demonstrate a role of RGS4 in the maintenance of chronic pain states in male and female mice. Using paradigms of peripheral inflammation and nerve injury, we show that the prevention of RGS4 action leads to recovery from mechanical and cold allodynia and increases the motivation for wheel running. Similarly, RGS4KO eliminates the duration of nocifensive behavior in the second phase of the formalin assay. Using the Complete Freud's Adjuvant (CFA) model of hindpaw inflammation we also demonstrate that downregulation of RGS4 in the adult ventral posterolateral thalamic nuclei promotes recovery from mechanical and cold allodynia. RNA sequencing analysis of thalamus (THL) from RGS4WT and RGS4KO mice points to many signal transduction modulators and transcription factors that are uniquely regulated in CFA-treated RGS4WT cohorts. Ingenuity pathway analysis suggests that several components of glutamatergic signaling are differentially affected by CFA treatment between RGS4WT and RGS4KO groups. Notably, Western blot analysis shows increased expression of metabotropic glutamate receptor 2 in THL synaptosomes of RGS4KO mice at time points at which they recover from mechanical allodynia. Overall, our study provides information on a novel intracellular pathway that contributes to the maintenance of chronic pain states and points to RGS4 as a potential therapeutic target.SIGNIFICANCE STATEMENTThere is an imminent need for safe and efficient chronic pain medications. Regulator of G-protein signaling 4 (RGS4) is a multifunctional signal transduction protein, widely expressed in the pain matrix. Here, we demonstrate that RGS4 plays a prominent role in the maintenance of chronic pain symptoms in male and female mice. Using genetically modified mice, we show a dynamic role of RGS4 in recovery from symptoms of sensory hypersensitivity deriving from hindpaw inflammation or hindlimb nerve injury. We also demonstrate an important role of RGS4 actions in gene expression patterns induced by chronic pain states in the mouse thalamus. Our findings provide novel insight into mechanisms associated with the maintenance of chronic pain states and demonstrate that interventions in RGS4 activity promote recovery from sensory hypersensitivity symptoms.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.